Hey Vineet, Ya saw that in September Holdings earlier MK also invested through QIP at 570-575 levels and now he has added more I believe or just transferred, not sure.

Few Triggers:-

1- USFDA Lifting the Import Alert ban this would result in recovery in their formulations exports in US can bounce back drastically
2- Launch of their Recombinant Albumin Drug in which they have CONFIDENTLY invested also, there is shortage of this drug all over the world with Huge TAM. This product has a 9 billion$ market.
3- Easing of input costs in their API business which has already showed some signs in last quarter.
4- Launching of their Aflibercept – a complex product in the ophthalmic range. Starting phase-3 trials in India. Trying to develop this particular product for the global market.
5- They have started focusing on Deleveraging which will result in decreasing Interest cost and inflate profits and cash flows.
6- Capex cycle has been already been stopped apart from few small amt of capex left for Albumin.
7- They are also working on developing APIs which are now 100% imported so china+1 can work here.
8- R&D expense will be rationalized without compromising new developments. which will have a positive impact on P&L .
9- Overall company has strong pipeline for for ANDA, NBE which will be soon reflect in numbers.

Invested at 232-235 levels

Hi, Creating this thread to discuss on Independent Power Producers (IPP) players in India incl. Adani Green, KPI, Tata Power, APL, NTPC etc…

So, this sector seems to be now consolidating under few names. Have included NTPC and APL as we will have to do cost comparison also.

1. My first question on this forum is-

APL – avg taffif is <Rs 3 /unit and AGL – avg tarif of 3.02/unit… Wasnt solar supposed to be cheaper?

2. 2nd would be –

Can some give a breakup of cost for end consumer / company. in case of traditional power and renewable power.

How much goes to IPP / distribution co/ Govt charges / etc… I understand this will vary from state to state but largely how is the distribution like…?

Sure.
I am talking of product, not of company. It may still do well.
Its mostly tender / institutional business (all MABs – except the patented ones of MNCs) sold at heavy discount to MRP.

Biologicals in india are not a good business. Adalimumab is a low margin business with heavy competition. This will be good if they get into Exports. But then registrations are lot more expensive.
Don’’t think if people in biologicals in India are making big money. Especially MABs